References
- Rudnick S A., Cadman E C., Capizzi R L. High dose cytosine arabinoside (HD ARAC) in refractory acute leukemia. Cancer 1979; 44: 1189–93
- Capizzi R L., Cheng Y-Chi. Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemia. Med Pediatr Oncol [Suppl] 1982; 1: 221–8
- Capizzi R L., Poole M, Cooper M R. Treatment of poor risk acute leukemia with sequential high-dose ara-C and asparaginase. Blood 1984; 63: 694–700
- Bennett J M., Catovsky D, Daniel M. Proposals for the classifications of acute leukemias. Br J Haematol 1976; 33: 451–8
- Castleberry R P., Crist W M., Holbrook T. The cytosine arabinoside (ara-C) syndrome. Med Pediatr Oncol 1981; 9: 257–64
- Preisler H D., Rustum Y, Henderson E S. Treatment of acute non-lymphocytic leukemia: Use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood 1979; 53: 455–64
- Weinstein H J., Mayer R J., Rosenthal D S. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 1983; 62: 315–19
- Baehner R L., Bernstein I D., Sather H. Contrasting benefits of two maintenance programs following identical induction in children with acute nonlymphocytic leukemia: A report from the Children's Cancer Study Group. Cancer Treat Rep 1984; 68: 1269–72
- Foon K A., Gale R P. Controversies in the therapy of acute myelogenous leukemia. Am J Med 1982; 72: 963–80
- Champlin R, Gale R P., Elashoff R. Prolonged survival in acute myelogenous leukemia without maintenance chemotherapy. Lancet 1984; 1: 894–6
- Vaughan W P., Karp J E., Burke P J. Long chemotherapy-free remissions after single-cycle timedsequential chemotherapy for acute myelocytic leukemia. Cancer 1980; 45: 859–65
- Vaughan W P., Karp J E., Burke P J. Two-cycle timedsequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 1984; 64: 975–80
- Madanat F T., Sullivan M P. Improved survival in young adults with acute granulocytic leukemia treated with combination therapy using cyclophosphamide, Oncovin, cytosine arabinoside, and prednisone. Cancer 1979; 44: 819–23
- Mayer R J., Weinstein H J., Coral F S. The role of intensive postinduction chemotherapy in the management of patients with acute myelogenous leukemia. Cancer Treat Rep 1982; 66: 1455–62
- Wolff S N., Marion G, Stein R S. High dose cytosine arabinoside and daunomycin for acute nonlymphocytic leukemia in first remission. Am Soc Clin Oncol Proc 1984; C-752
- Capizzi R, Cooper R, Stuart G. Sequential high dose ara-C and asparaginase (HiDAC-Asp) remission induction and HiDAC remission intensification in previously untreated patients with AML. Am Soc Clin Oncol Proc 1984; C-811